I see them being incorporated into clinical practice and that would give dementia care a great benefit with more accurate diagnosis. But I do see an important role for tau-PET imaging compared to the plasma or the CSF biomarkers because it gives us the spatial paradigm of where the tau is in the brain, not only the magnitude and that would correlate better with biological staging. And that would probably be the gold standard, even when people try to use different plasma biomarkers to try and predict the biological staging, they would be using the tau-PET as a gold standard...
I see them being incorporated into clinical practice and that would give dementia care a great benefit with more accurate diagnosis. But I do see an important role for tau-PET imaging compared to the plasma or the CSF biomarkers because it gives us the spatial paradigm of where the tau is in the brain, not only the magnitude and that would correlate better with biological staging. And that would probably be the gold standard, even when people try to use different plasma biomarkers to try and predict the biological staging, they would be using the tau-PET as a gold standard. And that’s how I see the future of biomarkers.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
